Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects
Author:
Affiliation:
1. Astellas Pharma, Inc.; Tokyo Japan
2. Department of Clinical Cardiovascular Research; Mie University Graduate School of Medicine; Mie Japan
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.50/fullpdf
Reference19 articles.
1. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation;Hart;Ann Intern Med.,2007
2. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic an thrombolytic therapy;Geerts;Chest.,2004
3. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl) benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor;Hirayama;J Med Chem.,2011
4. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery;Eriksson;J Thromb Haemost.,2007
5. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2);Eriksson;J Thromb Haemost.,2010
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3